FORA Capital’s GSK GSK Stock Holding History

FORA Capital’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-32,531	Closed	-$1.1M	–	562
2024 Q4	$1.1M	Buy	+32,531	New	+$1.17M	0.13%	190
2023 Q4	–	Sell	-7,056	Closed	-$256K	–	514
2023 Q3	$256K	Buy	+7,056	New	+$250K	0.02%	404
2023 Q2	–	Sell	-55,055	Closed	-$1.96M	–	461
2023 Q1	$1.96M	Buy	55,055 +36,396	+195%	+$1.27M	0.2%	146
2022 Q4	$656K	Sell	18,659 -63,737	-77%	-$2.12M	0.11%	228
2022 Q3	$2.42M	Buy	+82,396	New	+$3.12M	0.47%	52
2021 Q4	–	Sell	-7,038	Closed	-$336K	–	375
2021 Q3	$336K	Buy	+7,038	New	+$354K	0.08%	262
2020 Q3	–	Sell	-2,106	Closed	-$107K	–	778
2020 Q2	$107K	Sell	2,106 -36,825	-95%	-$1.89M	0.04%	473
2020 Q1	$1.84M	Buy	38,931 +20,028	+106%	+$1.07M	0.4%	50
2019 Q4	$1.11M	Buy	+18,903	New	+$1.05M	0.11%	244

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FORA Capital's GSK Position: Q1 2025 in Review

FORA Capital sold out of GSK (GSK) in Q1 2025, closing a stake of 32,531 shares — an estimated $1.1M sold.

FORA Capital first reported a position in GSK in Q4 2019 and held it in 9 quarters. The position peaked at $2.42M in Q3 2022. 857 funds tracked by Wall St. Rank hold GSK as of Q1 2025.

FORA Capital reported no remaining GSK position as of Q1 2025 after selling out during the quarter.
FORA Capital sold 32,531 GSK shares in Q1 2025, an estimated $1.1M.
FORA Capital first reported a position in GSK in Q4 2019 and held it in 9 quarters.
FORA Capital's GSK position peaked at $2.42M in Q3 2022.
857 funds tracked by Wall St. Rank held GSK as of Q1 2025.

Based on FORA Capital's 13F filing for Q1 2025, filed 14 May 2025.